Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) Operating Expenses (2019 - 2025)

Historic Operating Expenses for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to $201.3 million.

  • Avidity Biosciences' Operating Expenses rose 10033.94% to $201.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $633.3 million, marking a year-over-year increase of 8916.06%. This contributed to the annual value of $389.8 million for FY2024, which is 5901.3% up from last year.
  • As of Q3 2025, Avidity Biosciences' Operating Expenses stood at $201.3 million, which was up 10033.94% from $175.0 million recorded in Q2 2025.
  • Avidity Biosciences' Operating Expenses' 5-year high stood at $201.3 million during Q3 2025, with a 5-year trough of $26.6 million in Q1 2021.
  • For the 5-year period, Avidity Biosciences' Operating Expenses averaged around $76.8 million, with its median value being $59.8 million (2023).
  • As far as peak fluctuations go, Avidity Biosciences' Operating Expenses surged by 25376.93% in 2021, and later soared by 1335.27% in 2023.
  • Quarter analysis of 5 years shows Avidity Biosciences' Operating Expenses stood at $40.4 million in 2021, then surged by 38.6% to $56.0 million in 2022, then rose by 23.11% to $68.9 million in 2023, then surged by 79.82% to $124.0 million in 2024, then skyrocketed by 62.37% to $201.3 million in 2025.
  • Its Operating Expenses stands at $201.3 million for Q3 2025, versus $175.0 million for Q2 2025 and $133.1 million for Q1 2025.